glp 1 drugs and addiction GLP-1 for Addiction: Hype or Hope? GLP-1 Receptor Agonists and Research

Epub 2004 Feb 5

THE FIT PROGRAM INCLUDED ADULT PATIENTS WITH CHRONIC ITP WHO HAD RECEIVED 1 PRIOR THERAPY FIT program patients were representative of the general adult chronic ITP population, including exposure to prior therapies TAVALISSE dosing 3 Starting dose of TAVALISSE: One 100 mg tablet BID Based on platelet count and tolerability, the dose could be increased to one 150 mg tablet BID at or after week 4 Patients who had a platelet count 50 x 10 9 /L at the time of rollover to the FIT-3 open-label extension study maintained their existing dose of TAVALISSE References: 1

BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a gastric body protection compound, studied mainly for tendon, muscle, and gut healing in rodents

Leboss, F

A powerful antioxidant topical lotion